Artivion announces presentation of late-breaking data from amds persevere and amds protect trials at the 39th european association for cardio-thoracic surgery (eacts) annual meeting

30-day data from the amds persevere trial demonstrates visceral malperfusion resolution in 83%, and renal malperfusion resolution in 74% of affected subjects post-amds implantation real-world data from the amds protect trial validate statistically significant positive outcomes demonstrated by the persevere and darts trials atlanta , oct. 13, 2025 /prnewswire/ -- artivion, inc. (nyse: aort), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from its amds persevere and protect trials were presented in late-breaking science presentations at the 39th european association for cardio-thoracic surgery (eacts) annual meeting in copenhagen, denmark. the amds persevere trial presentation highlighted positive 30-day data focused on a subset of patients with visceral and renal malperfusion.
AORT Ratings Summary
AORT Quant Ranking